KINE SCIENCES Co., Ltd.

KINE SCIENCES is a company that researches and develops ultra-small immune-peptide drugs based on functional immunology for chronic neuroinflammatory and autoimmune diseases. We were the first to identify the anti-inflammatory function of ERDR1, and based on this, we have independently established a development process for immune-modulating functional immune-peptide drugs derived from cytokine-based peptides. We possess a comprehensive peptide library consisting of approximately 200 diverse peptide candidates. We have 6 assets with 19 indications in the pipeline including Rheumatoid Arthritis, Inflammatory Bowel Disease, Alzheimer’s Disease and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Our ultra-small immune-peptides offer differentiated advantages, including excellent pharmacokinetic and pharmacodynamic (long PD effect) profiles, low immunogenicity and antigenicity, cost-effective production, and the potential for oral administration. We are primarily focused on our lead asset, KINE-101, an ultra-small peptide (<1 kDa) composed of 9 amino acids, targeting Treg cells as a treatment candidate for CIDP. Following the successful completion of a Phase I clinical trial in healthy volunteers in the US, which demonstrated a good safety profile, a Phase Ib/IIa clinical study is currently underway in Korea with CIDP patients who have previously received at least one frontline treatment regimen (first patients dosed). In addition, KINE-501, a post-modification form of KINE-101 designed to enhance therapeutic efficacy, is a candidate for Alzheimer's disease treatment, targeting microglial cells, the immune cells of the brain. KINE-501 can cross effectively the blood-brain barrier (BBB) and has the unique ability to simultaneously induce the removal of amyloid-beta and exert anti-inflammatory and antioxidant effects. We are currently seeking a partner for the co-development, licensing or funding of KINE-101 and KINE-501.